BACKGROUND: Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans. METHODS: We tested the in vitro effect of the CCR5 antagonist maraviroc on lymphocyte function and chemotaxis. We then enrolled 38 high-risk patients in a single-group phase 1 and 2 study of reduced-intensity allogeneic HSCT that combined maraviroc with standard GVHD prophylaxis. RESULTS: Maraviroc inhibited CCR5 internalization and lymphocyte chemotaxis in vitro without impairing T-cell function or formation of hematopoietic-cell colonies. In 35 patients who could be evaluated, the cumulative incidence rate (±SE) of grade II to IV acute GVHD was low at 14.7±6.2% on day 100 and 23.6±7.4% on day 180. Acute liver and gut GVHD were not observed before day 100 and remained uncommon before day 180, resulting in a low cumulative incidence of grade III or IV GVHD on day 180 (5.9±4.1%). The 1-year rate of death that was not preceded by disease relapse was 11.7±5.6% without excessive rates of relapse or infection. Serum from patients receiving maraviroc prevented CCR5 internalization by CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of antichemotactic activity. CONCLUSIONS: In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00948753.).
BACKGROUND:Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans. METHODS: We tested the in vitro effect of the CCR5 antagonist maraviroc on lymphocyte function and chemotaxis. We then enrolled 38 high-risk patients in a single-group phase 1 and 2 study of reduced-intensity allogeneic HSCT that combined maraviroc with standard GVHD prophylaxis. RESULTS:Maraviroc inhibited CCR5 internalization and lymphocyte chemotaxis in vitro without impairing T-cell function or formation of hematopoietic-cell colonies. In 35 patients who could be evaluated, the cumulative incidence rate (±SE) of grade II to IV acute GVHD was low at 14.7±6.2% on day 100 and 23.6±7.4% on day 180. Acute liver and gut GVHD were not observed before day 100 and remained uncommon before day 180, resulting in a low cumulative incidence of grade III or IV GVHD on day 180 (5.9±4.1%). The 1-year rate of death that was not preceded by disease relapse was 11.7±5.6% without excessive rates of relapse or infection. Serum from patients receiving maraviroc prevented CCR5 internalization by CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of antichemotactic activity. CONCLUSIONS: In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00948753.).
Authors: Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn Journal: Blood Date: 2011-10-18 Impact factor: 22.113
Authors: John E Levine; Brent Logan; Juan Wu; Amin M Alousi; Vincent Ho; Javier Bolaños-Meade; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-06-09 Impact factor: 5.742
Authors: Mary E D Flowers; Yoshihiro Inamoto; Paul A Carpenter; Stephanie J Lee; Hans-Peter Kiem; Effie W Petersdorf; Shalini E Pereira; Richard A Nash; Marco Mielcarek; Matthew L Fero; Edus H Warren; Jean E Sanders; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin Journal: Blood Date: 2011-01-24 Impact factor: 22.113
Authors: Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng Journal: Blood Date: 2009-07-14 Impact factor: 22.113
Authors: David H McDermott; Susan E Conway; Tao Wang; Stacy M Ricklefs; Manza A Agovi; Stephen F Porcella; Huong Thi Bich Tran; Edgar Milford; Stephen Spellman; Reza Abdi Journal: Blood Date: 2010-01-12 Impact factor: 22.113
Authors: S M Luger; O Ringdén; M-J Zhang; W S Pérez; M R Bishop; M Bornhauser; C N Bredeson; M S Cairo; E A Copelan; R P Gale; S A Giralt; Z Gulbas; V Gupta; G A Hale; H M Lazarus; V A Lewis; M C Lill; P L McCarthy; D J Weisdorf; M A Pulsipher Journal: Bone Marrow Transplant Date: 2011-03-28 Impact factor: 5.483
Authors: Nina C Zitzer; Katiri Snyder; Xiamoei Meng; Patricia A Taylor; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Ramiro Garzon; Parvathi Ranganathan Journal: J Immunol Date: 2018-05-02 Impact factor: 5.422
Authors: Peter W Hunt; Nancy S Shulman; Timothy L Hayes; Viktor Dahl; Ma Somsouk; Nicholas T Funderburg; Bridget McLaughlin; Alan L Landay; Oluwatoyin Adeyemi; Lee E Gilman; Brian Clagett; Benigno Rodriguez; Jeffrey N Martin; Timothy W Schacker; Barbara L Shacklett; Sarah Palmer; Michael M Lederman; Steven G Deeks Journal: Blood Date: 2013-04-15 Impact factor: 22.113
Authors: Clinton Yam; Lisa Crisalli; Selina M Luger; Alison W Loren; Elizabeth O Hexner; Noelle V Frey; James K Mangan; Amy Gao; Edward A Stadtmauer; David L Porter; Ran Reshef Journal: Am J Hematol Date: 2016-07-12 Impact factor: 10.047
Authors: Wei Li; Liangyi Liu; Aurelie Gomez; Jilu Zhang; Abdulraouf Ramadan; Qing Zhang; Sung W Choi; Peng Zhang; Joel K Greenson; Chen Liu; Di Jiang; Elizabeth Virts; Stephanie L Kelich; Hong Wei Chu; Ryan Flynn; Bruce R Blazar; Helmut Hanenberg; Samir Hanash; Sophie Paczesny Journal: JCI Insight Date: 2016-05-05